Phagos, a Paris-based biotechnology company developing AI-driven bacteriophage therapies as sustainable alternatives to antibiotics, has raised €25 million in Series A funding.
The round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with additional participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.
Founded in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos is the first company authorised in the EU to market personalised phage-based veterinary treatments, marking a regulatory milestone in the fight against antimicrobial resistance (AMR).
“Phage therapy can transform medicine just as antibiotics did a century ago,” said Pantalis and James, co-founders of Phagos. “This funding enables us to accelerate our mission to make phage-based alternatives fast, effective, and accessible — starting with animal health today and advancing toward human health tomorrow.”
Tackling the antibiotic resistance crisis
Antimicrobial resistance is one of the most pressing challenges in both healthcare and agriculture. Bacterial resistance now renders one in three livestock antibiotics ineffective, a figure that has tripled since 2000. Beyond its impact on animal health, AMR contributes to global food waste, economic losses, and millions of preventable deaths annually.
Phagos’ approach combines microbiology and artificial intelligence to create ultra-targeted phage therapies that precisely eliminate harmful bacteria such as Salmonella and E. coli without disrupting healthy microbiota.
Its AI-powered phage discovery platform predicts interactions between phages and bacteria, enabling scalable, rapid, and tailored treatments for each infection. This technology gives the company a clear edge in developing next-generation solutions for both veterinary and future human applications.
“Antimicrobial resistance is a defining challenge for global food systems,” said Anne-Valérie Bach, Managing Director at CapAgro. “With its unprecedented regulatory approval and AI discovery platform, Phagos is proving that phage therapies are not a future concept, but an actionable alternative to antibiotics.”
Advertisement
Scaling global impact through science and technology
The new funding will support:
- Expansion of Phagos’ veterinary product line across Europe, Asia, and the Americas
- Advancement of its proprietary AI platform for faster and more precise phage discovery
- R&D acceleration to extend applications toward human therapeutics
- Recruitment across scientific, engineering, and commercial teams to scale global operations
Currently, 90% of Phagos’ workforce consists of scientific and technical experts, reflecting its deep commitment to research excellence and data-driven innovation.
“Phagos’ pioneering platform offers an effective, scalable alternative to antibiotics,” said Rob Kniaz, Founder and Emeritus Partner at Hoxton Ventures. “It’s positioned to redefine how bacterial infections are treated, reshaping both animal and human health in a multi-billion-euro global market.”
About Phagos
Phagos is a Paris-based biotechnology company pioneering the development of AI-enhanced bacteriophage therapies to fight bacterial infections and antibiotic resistance. The company creates personalised, precision phage treatments for animals and is expanding toward human healthcare applications.
Founded in 2021, the startup combines advanced microbiology and artificial intelligence to deliver sustainable, scalable alternatives to antibiotics — driving innovation for a healthier, more resilient future.
